For example, the University of Virginia Health System saw an increase in CRE transmission in 2010, Kyle Enfield, MD, the medical director of the system’s ICU, wrote in a Centers for Disease Control and Prevention blog post.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Dr. Enfield and others first attempted to limit the facility’s exposure to CRE and another nosocomial pathogen, extensively drug-resistant Acinetobacter baumannii, but those attempts, based on standard infection control practices, failed, Dr. Enfield wrote.
So, the organization used a bundled set of interventions to assess the prevalence of CRE and XDR-AB colonization in the ICU. The bundled approach brought the CRE incidence down to 0.1 percent of patient days and eliminated drug-resistant A. baumannii completely.
Those measures are now recommended practice in the CDC’s 2012 Carbapenem-resistant Enterobacteriaceae Toolkit.
The experience was documented in a study recently published in Infection Control and Hospital Epidemiology, which concluded that the health system’s experience shows the effectiveness of the CDC toolkit.
More Articles on Infection Prevention:
NIH Starts Clinical Trial for C. Diff Drug
Patient Safety Tool: Medical Mattress Inspection, Repair Guide
Microsoft Sells Patent for Keyboard, Touchscreen Surface Disinfectant to Viogurad
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
